In 4Q24, the Company experienced a 28% yearover-year increase in total revenues, reaching $45.0M. This growth was driven by a significant rise in international revenues across both product sales and services, with strength in the Middle East tracer diagnostics projects. Canada also saw strong Y/Y growth of 19.5%. Results were mixed in the U.S. with product sales increasing 29.1 and services revenues decreasing 9.5%. Going forward we expect that the Company will continue to see modest revenue growth through FY25 despite the threat of increasing tariffs. Consolidated gross margins expanded from 36.6% in 4Q23 to 43.1% in 4Q24.